CA2345137A1 - Mglur5 antagonists for the treatment of pain and anxiety - Google Patents

Mglur5 antagonists for the treatment of pain and anxiety Download PDF

Info

Publication number
CA2345137A1
CA2345137A1 CA002345137A CA2345137A CA2345137A1 CA 2345137 A1 CA2345137 A1 CA 2345137A1 CA 002345137 A CA002345137 A CA 002345137A CA 2345137 A CA2345137 A CA 2345137A CA 2345137 A1 CA2345137 A1 CA 2345137A1
Authority
CA
Canada
Prior art keywords
antagonist
pain
treatment
mglur
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345137A
Other languages
English (en)
French (fr)
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stephen D. Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Gonul Velicelebi
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2345137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Individual filed Critical Individual
Publication of CA2345137A1 publication Critical patent/CA2345137A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA002345137A 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety Abandoned CA2345137A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9821503.1 1998-10-02
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
US09/220,813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number Publication Date
CA2345137A1 true CA2345137A1 (en) 2000-04-13

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345137A Abandoned CA2345137A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
KR100545906B1 (ko) * 2000-12-22 2006-01-26 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
RS60199B1 (sr) 2015-06-03 2020-06-30 Hoffmann La Roche Derivati etinila
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68907095T2 (de) * 1988-03-21 1994-01-05 Boehringer Ingelheim Pharma Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
ID29095A (id) 2001-07-26
ES2213389T3 (es) 2004-08-16
AU6198499A (en) 2000-04-26
BR9914215A (pt) 2001-07-03
PT1117403E (pt) 2004-04-30
CN1187048C (zh) 2005-02-02
WO2000020001A1 (en) 2000-04-13
NO20011440D0 (no) 2001-03-21
DE69913548T2 (de) 2004-09-23
RU2232017C2 (ru) 2004-07-10
ATE255894T1 (de) 2003-12-15
EP1117403A1 (en) 2001-07-25
IL142047A0 (en) 2002-03-10
JP2002526408A (ja) 2002-08-20
NO20011440L (no) 2001-05-15
CN1321087A (zh) 2001-11-07
DK1117403T3 (da) 2004-04-13
SK4382001A3 (en) 2001-08-06
PL202906B1 (pl) 2009-08-31
NZ510743A (en) 2003-10-31
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
EP1117403B1 (en) 2003-12-10
KR20010088832A (ko) 2001-09-28
AU765644B2 (en) 2003-09-25
HUP0200553A3 (en) 2002-11-28
HUP0200553A2 (hu) 2002-07-29
PL346876A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
AU765644B2 (en) mGluR5 antagonists for the treatment of pain and anxiety
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
EP1272218B1 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US4486436A (en) Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
CN102821765A (zh) 改良神经传导速度的方法和组合物
US20070265279A1 (en) Use of mGluR5 antagonists for the treatment of pruritic conditions
US20120289542A1 (en) Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US4464376A (en) Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
SE466481B (sv) Analgetiska och anti-inflammatoriska kompositioner innefattande koffein
Li et al. Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I2 receptor ligands
JPH11501934A (ja) ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
US20100203084A1 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
WO2006128035A2 (en) Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20050187239A1 (en) Synergistic l-methadone compositions and methods of use thereof
US20130137725A1 (en) Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
Tokunaga et al. Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued